그레이브스병 : 시장 전망, 역학, 경쟁 구도, 시장 예측 보고서(2025-2035년)

Graves' Disease Market Outlook

Thelansis's "Graves' Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Graves' Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Graves' Disease Overview

Graves' disease is an autoimmune disorder in which thyroid-stimulating immunoglobulins activate the TSH receptor, causing hyperthyroidism with symptoms such as weight loss, heat intolerance, palpitations, tremor, and goiter; it commonly produces thyroid eye disease (orbitopathy) and occasionally pretibial myxedema. Untreated hyperthyroidism can cause cardiac complications, bone loss, menstrual and fertility disturbances, and risks during pregnancy for both mother and fetus. Graves' disease often coexists with other autoimmune conditions (for example, type 1 diabetes, pernicious anemia, vitiligo, and rheumatoid arthritis). Diagnosis is clinical and biochemical (suppressed TSH, elevated free T4/T3) with supportive testing for TSH-receptor antibodies and thyroid imaging when indicated; treatment options include antithyroid drugs, radioactive iodine, or thyroidectomy, with specific management for orbitopathy as needed.

Key Highlights

• In France, incident Graves' disease cases are projected to increase from 34,206 in 2025 to 35,982 by 2035.
• Graves' disease is the leading cause of hyperthyroidism and disproportionately affects women.
• Disease burden is driven by recurrent hyperthyroidism and thyroid eye disease complications.
• Growing awareness and earlier diagnosis are improving disease management.

Market Overview

• The Italy Graves' disease market is projected to grow from $220.5M in 2025 to $294M by 2035.
• Market growth is supported by:
• Increasing diagnosis and treatment rates
• Adoption of therapies for thyroid eye disease
• Future growth will depend on targeted immunomodulatory approaches and improved long-term disease control.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Argenx
• Merida Biosciences
• Biohaven Therapeutics Ltd.
• Immunovant Sciences GmbH
• Sanofi
• Changchun GeneScience Pharmaceutical Co., Ltd.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)